Haloperidol-induced extrapyramidal reaction: lack of protective effect by vitamin E.
Haloperidol treatment has been shown to produce oxidative stress in patients with acute psychosis. Oxidative stress has also been implicated in the extrapyramidal symptoms (EPS) produced by haloperidol. Supporting the oxidative stress hypothesis, vitamin E (antioxidant) has demonstrated therapeutic efficacy in idiopathic parkinsonism. The prophylactic efficacy of vitamin E (antioxidant) on haloperidol-induced EPS was examined in a randomized controlled trial. The sample consisted of 24 acute psychotic patients hospitalized for a 2-week trial. All patients received oral haloperidol 10 mg/day. The sample was equally randomized to receive either haloperidol alone or haloperidol + vitamin E (3200 IU/day). EPS was rated at recruitment, both live and with video records, and on days 3, 7, 10 and 14. Psychopathology was rated at recruitment and weekly thereafter. Vitamin E had no prophylactic effect on drug-induced EPS, though it did not interfere with the therapeutic efficacy of haloperidol.
Eranti
V S
VS
Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka, India.
Gangadhar
B N
BN
Janakiramaiah
N
N
D000293:Adolescent; D000328:Adult; D000975:Antioxidants / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001480:Basal Ganglia Diseases / Q000139:chemically induced / Q000517:prevention & control*; D004311:Double-Blind Method; D006220:Haloperidol / Q000009:adverse effects*; D006801:Humans; D008297:Male; D011446:Prospective Studies; D011569:Psychiatric Status Rating Scales; D013997:Time Factors; D014810:Vitamin E / Q000627:therapeutic use*
D000975:Antioxidants; D014150:Antipsychotic Agents; D014810:Vitamin E; D006220:Haloperidol